|
|
News Breaks | | | | October 9, 2012 | | 09:02 EDT |  | SGEN, RHHBY | Seattle Genetics to receive milestone payments as Genentech advances two ADCs
Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma. | |
|
News For SGEN;RHHBY From The Last 14 Days Check below for free stories on SGEN;RHHBY the last two weeks. |
|
|
| June 19, 2013 | | 10:46 EDT |  | RHHBY | Alexion mentioned as possible target for Roche in London Times
Reference Link | | | 09:05 EDT | | SGEN | Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS
Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma. The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma being held June 19–22, 2013 in Lugano, Switzerland. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. “These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population,” said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. “ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.” | | | 08:45 EDT |  | RHHBY | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | June 13, 2013 | | 11:02 EDT | | RHHBY | Leerink's major pharma analyst holds an analyst/Industry conference call
 Subscribe for More Information | | | June 11, 2013 | | 08:01 EDT | | RHHBY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | June 10, 2013 | | 09:19 EDT | | SGEN | Seattle Genetics announces start of Hodgkin Lymphoma treatment phase 1/2 trial
Seattle Genetics announced the initiation of a phase 1/2 clinical trial evaluating Adcentris in combination with bendamustine for patients with Hodgkin lymphoma after first relapse. The multi-phase study is divided into two cohorts to determine the recommended dosing level and tolerability of combination use and to assess the complete remission rate associated with Adcentris in combination with bendamustine. Of the 14 evaluable patients, 12 patients had an objective response rate, including seven complete remissions and five partial remissions. The most common Grade 1 or 2 adverse events were peripheral sensory neuropathy, acneiform rash, AST elevation, and fatigue. Grade 3 adverse events were rash acneiform and urinary tract infection and there were no Grade 4 adverse events. | | | 07:40 EDT | | RHHBY, SGEN | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | 07:24 EDT | | RHHBY | European Society of Human Genetics to host a conference
Subscribe for More Information | |
|
|
|
|
|
|
